Catawba Research, a global clinical research organization (CRO), announced a new collaboration with Bingli Inc., which provides AI-guided diagnosis, disease management, and navigation for patients and healthcare providers. All Catawba’s clinical studies may now offer candidates pre-screening via Bingli’s smart clinical trial technology that includes rigorous disease scoring system outcomes and delivers a highly enriched candidate pool for real-time recruitment management.
“At Catawba Research, we are creating value in clinical research by identifying and incorporating the best technology solutions to speed recruitment, the biggest challenge currently facing our industry,” said Catawba Chief Executive Officer Andrew Silverman, Ph.D. “Partnering with Bingli gives us a powerful tool to streamline participation, reduce site burden, and save time for potential participants as they explore their clinical trial options.”
Applying Bingli’s technology platform will allow Catawba to reduce trial costs, eliminating a higher proportion of ineligible subjects compared to traditional pre-screening methods. The AI solution sends approximately 3% of candidates to sites, reducing failed screens by up to 75%. With a Bingli referral, a candidate is three to four times as likely to be eligible. Bingli delivers extraordinary value to sponsors and CROs by reducing site burden and delivering candidates highly likely to convert to enrolled subjects.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!